Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OrthoPediatrics Corp. (NASDAQ: KIDS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. OrthoPediatrics is a Delaware-incorporated orthopedic medical device company focused on pediatric orthopedics, and its filings offer detailed information on its financial condition, operations, and governance.
Investors can review current reports on Form 8-K, where OrthoPediatrics reports material events such as quarterly earnings releases, preliminary unaudited revenue updates, revisions to financial guidance, and presentations to investors and analysts. The company also uses Form 8-K to disclose board changes, including director retirements and new appointments, and to furnish press releases related to business developments like OPSB expansion.
In addition to 8-Ks, OrthoPediatrics files periodic reports such as Form 10-Q and Form 10-K, which contain unaudited and audited financial statements, segment information, and risk factor discussions referenced in its news releases. These documents provide context on revenue by category (trauma and deformity, scoliosis, sports medicine/other procedures, and specialty bracing), operating expenses, restructuring charges, intangible asset impairments, and non-GAAP measures such as adjusted EBITDA.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, major cost items, and business drivers. Users can also track real-time updates as new filings are posted to EDGAR, including any future Forms 4 reporting insider transactions, proxy statements detailing director compensation, and other governance-related documents. This centralized view of KIDS filings allows investors, analysts, and researchers to examine OrthoPediatrics’ regulatory history, financial disclosures, and corporate actions in one place, supported by AI-generated explanations that clarify complex sections of the filings.
OrthoPediatrics Corp. reports strong expansion as a pediatric-focused medical device and bracing company, targeting a global pediatric orthopedic market it estimates at $6.2 billion, including over $2.8 billion in the United States.
The company markets 87 surgical and specialized bracing systems across trauma and deformity, scoliosis and sports medicine, and has grown revenue from $10.2 million in 2011 to $236.3 million in the year ended December 31, 2025, a 25.2% compound annual growth rate. For 2025, trauma and deformity generated $166.3 million (70% of revenue), scoliosis $66.0 million (28%), and sports medicine/other $4.0 million (2%).
The report highlights an active acquisition program, including the 2024 purchase of Boston Brace International, Inc. and multiple O&P clinic roll-ups in the United States, Europe and Brazil, alongside new technology partnerships and an expanded credit and convertible note structure with Braidwell. As of December 31, 2025, OrthoPediatrics had consolidated total assets of $508.6 million, liabilities of $162.0 million, stockholders’ equity of $346.6 million, and 602 full-time equivalent employees.
OrthoPediatrics Corp. furnished an investor presentation outlining its 2025 performance and 2026 outlook. For 2025, revenue reached $236.3 million, up 15% from $204.7 million, with gross margin at 73%. The company still posted a net loss of $39.6 million, or $1.69 per diluted share, but delivered Adjusted EBITDA of $14.8 million and improved free cash flow to a $15 million outflow from $42 million the prior year.
The presentation highlights long-term double-digit revenue growth, a broad pediatric-focused product portfolio and contributions from acquisitions such as Boston Orthotics & Prosthetics. Management’s 2026 guidance targets revenue of $262.0 to $266.0 million, Adjusted EBITDA of about $25 million and breakeven free cash flow, emphasizing ongoing investment in new technologies and clinic expansion.
OrthoPediatrics Corp. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable overall. Full year revenue reached $236.3 million, up 15% from $204.7 million in 2024, with U.S. revenue of $186.4 million and international revenue of $49.9 million, both rising 15–16%.
Fourth quarter 2025 revenue was $61.6 million, up 17% year over year, and gross margin improved to 73.2%. Adjusted EBITDA grew to $4.8 million in the quarter and $14.8 million for the year, but the company still posted a 2025 net loss of $39.6 million, or $1.69 per share.
Cash and investments totaled $62.9 million as of December 31, 2025, and the company generated about $9.8 million of free cash flow in the fourth quarter, its first positive free cash flow quarter. For 2026, OrthoPediatrics projects revenue of $262.0–$266.0 million, adjusted EBITDA of $25.0 million, and breakeven free cash flow.
OrthoPediatrics Corp. filed a current report describing upcoming presentations by its executive officers to investors and analysts. The company has prepared an investor presentation that is included as Exhibit 99.1 and may be used, in whole or in part, during these meetings. The investor presentation and related information are being furnished under a Regulation FD disclosure item and are not considered filed for liability purposes under the Securities Exchange Act of 1934 or automatically incorporated into other securities law filings.
OrthoPediatrics Corp. furnished an update on its business by issuing a press release with preliminary unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025. The company also provided management’s projection of 2026 net revenue and offered a related business update. These figures are described as preliminary estimates that remain subject to completion of the audit process and may change, and the company highlights that actual 2025 and 2026 net revenue could differ materially from the estimates and projections. The disclosure emphasizes that these statements are forward-looking and directs readers to previously disclosed risk factors for elements that could cause results to vary.
OrthoPediatrics (KIDS) filed a Form 3 reporting the initial beneficial ownership of a director. The filing states 0 shares of common stock beneficially owned and lists no derivative securities. The event date for this report is 11/10/2025. The form was filed by one reporting person, with a Power of Attorney on file.
OrthoPediatrics Corp. reported Q3 2025 results. Net revenue rose to $61,250 thousand from $54,573 thousand, with gross profit of $45,274 thousand. Operating expenses included intangible asset impairment of $2,268 thousand and restructuring of $2,294 thousand, resulting in an operating loss of $9,428 thousand versus $5,566 thousand a year ago. Net loss was $11,773 thousand, or $0.50 per share.
For the nine months, revenue reached $174,743 thousand versus $152,060 thousand, while net loss was $29,545 thousand. Cash was $16,826 thousand and short‑term investments were $40,902 thousand as of September 30, 2025. The company had a term loan of $51,000 thousand and a $50,000 thousand convertible note outstanding. It drew $25,000 thousand from its delayed‑draw term loan on June 27, 2025. Net cash used in operating activities was $15,199 thousand year‑to‑date.
U.S. sales were $48,718 thousand and international sales were $12,532 thousand in Q3. Shares outstanding were 25,077,330 as of October 28, 2025.
OrthoPediatrics Corp. (KIDS) furnished an investor presentation. The company’s executive officers plan upcoming presentations to investors and analysts and intend to use materials included as Exhibit 99.1, titled “OrthoPediatrics Corp. Investor Presentation” dated October 2025.
The materials are provided under Item 7.01 (Regulation FD) and are furnished, not filed, meaning they are not subject to liability under Section 18 of the Exchange Act and are not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
OrthoPediatrics Corp. furnished an 8-K announcing its earnings for the quarter ended September 30, 2025. The press release, including unaudited condensed consolidated financial statements and other financial data, is attached as Exhibit 99.1 and incorporated by reference.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.